Sensitivity landmark analyses stratified by timeframe of semaglutide initiation Given that semaglutide was initially approved for type 2 diabetes, with initial obesity approval in 2021, it is possible that inclusion of non-diabetic patients could introduce indication bias in the previously described analyses, as non-diabetic patients enrolled before 2021 likely represent off-label use and may differ systematically from those treated after approval
Dehydration magnifies fatigue and dizziness, so drinking 810 glasses of water daily becomes critical
Nanotech Rev 9:6169 Xie Q, Wang X, Zhang G, Zhou D, Zhao Y, Liu H, Duan J, Yu D, Sang Y (2024) Ultrasmall Fe 3 O 4 nanoparticles self-assembly induced dual-mode T1/T2-weighted magnetic resonance imaging and enhanced tumor synergetic theranostics
Before you panic, know this: NAION is incredibly rare, even in people who take semaglutide